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ABSTRACT  Bronchiectasis in adults is a chronic disorder associated with poor quality of life and frequent exacerbations in 
many patients. There have been no previous international guidelines. 
The European Respiratory Society guidelines for the management of adult bronchiectasis describe the appropriate 
investigation and treatment strategies determined by a systematic review of the literature. 
A multidisciplinary group representing respiratory medicine, microbiology, physiotherapy, thoracic surgery, primary care, 
methodology and patients considered the most relevant clinical questions (for both clinicians and patients) related to 
management of bronchiectasis. Nine key clinical questions were generated and a systematic review was conducted to 
identify published systematic reviews, randomised clinical trials and observational studies that answered these questions. We 
used the GRADE approach to define the quality of the evidence and the level of recommendations. The resulting guideline 
addresses the investigation of underlying causes of bronchiectasis, treatment of exacerbations, pathogen eradication, long term 
antibiotic treatment, anti-inflammatories, mucoactive drugs, bronchodilators, surgical treatment and respiratory physiotherapy. 
These recommendations can be used to benchmark quality of care for people with bronchiectasis across Europe and to improve 
outcomes. 
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Scope and objectives 
This guideline provides evidence-based recommendations for the management of adult patients with bronchiectasis. It only 
applies to patients with clinically significant bronchiectasis, defined by the presence of both permanent bronchial dilatation 
on computed tomography (CT) scanning and the clinical syndrome of cough, sputum production and/or recurrent respiratory 
infections. Radiological bronchiectasis may be evident in healthy asymptomatic individuals, particularly in the elderly [1] or 
may occur, for example, due to traction in interstitial lung disease. Such radiological bronchiectasis without clinical 
symptoms are not addressed in this guideline. The following conditions are also excluded: cystic fibrosis bronchiectasis, which 
has a distinct pathophysiology and treatment pathway, children with bronchiectasis, treatment of primary immunodeficiencies 
and non-tuberculous mycobacteria (NTM), where disease specific therapy is indicated. The majority of these clinical issues are 
addressed in other guidelines. 
This guideline document does not address clinical and radiological diagnosis of bronchiectasis but rather focuses on key 
questions in management. Areas such as smoking cessation, nutrition, influenza and pneumococcal vaccination among other 
aspects of general management are not specifically addressed in this document. Readers are referred to relevance guidelines 
and national policies. A guideline document cannot address the full complexity of a disease such as bronchiectasis, hence all 
recommendations should be interpreted taking into account the clinical circumstances and patients’ perceptions, values 
and preferences. 
Table 1 provides a framework to understand the recommendations made in this document [2, 3]. 
The target audience for this guideline are all stakeholders involved bronchiectasis care. This includes specialists in respiratory 
medicine, infectious diseases, clinical microbiology, general internists, specialists in thoracic surgery, primary care physicians, 
pharmacists, respiratory physiotherapists, specialist nurses, regulatory authorities, pharmaceutical companies and policy 
makers. The guideline is also to inform people with bronchiectasis to help them to discuss with their care teams and to access 
appropriate care. 
 
Introduction 
Bronchiectasis is a chronic respiratory disease characterised by a clinical syndrome of cough, sputum production and 
bronchial infection, and radiologically by abnormal and permanent dilatation of the bronchi. The objectives of treatment in 
bronchiectasis are to prevent exacerbations, reduce symptoms, 
 
 
 
Support statement: The task force was funded by the European Respiratory Society. Funding information for this article has been deposited with 
the Crossref Funder Registry. 
Conflict of interest: D. Rigau and T. Tonia act as methodologists for the European Respiratory Society. All other disclosures can be found 
alongside this article at erj.ersjournals.com 
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  TABLE 1 Understanding the recommendations made in this document   
Target group Strong recommendations# Conditional (weak) recommendations 
 
 
Patients All or almost all informed people would choose the 
recommended choice for or against an intervention. 
Clinicians Most patients should receive the recommended 
course of action. 
 
 
 
 
Policy makers  The recommendation can be adopted as a policy in most 
situations. 
Most informed people would choose the recommended course of action, but a 
substantial number would not. 
 
Recognise that different choices will be appropriate for different patients. Clinicians 
and other healthcare providers need to devote more time to the process of 
shared decision making by which they ensure that the informed choice reflects 
individual values and preferences; decision aids and shared decision making are 
particularly useful. 
Policy making will require substantial debate and involvement of many 
stakeholders. 
 
 
#: strong recommendations based on high quality evidence will apply to most patients for whom these recommendations are made, but they may not apply to all patients 
in all conditions; no recommendation can take into account all of the unique features of individual patients and clinical circumstances. 
 
 
 
 
improve quality of life and stop disease progression. Cough and sputum production, along with breathlessness are the 
most frequent symptoms but rhinosinusitis, fatigue, haemoptysis and thoracic pain are also common [4]. Quality of life 
impairment in bronchiectasis is equivalent in terms of scores on the St George’s Respiratory Questionnaire (SGRQ) to severe 
chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis and other disabling respiratory diseases [5, 6]. 
Exacerbations of bronchiectasis are key targets for therapy as they are major determinants of healthcare costs. They are 
associated with increased airways and systemic inflammation [7] and progressive lung damage [8, 9]. In addition, more severe 
and more frequent exacerbations are associated with worse quality of life, daily symptoms [10], lung function decline [11], and 
mortality [9]. Consequently, the majority of therapeutic interventions are aimed at reducing exacerbations. Despite current 
treatment approaches, European registry data shows that approximately 50% of European bronchiectasis patients have two or 
more exacerbations per year and one third require at least one hospitalisation per year [12]. 
Our understanding of what causes symptoms and exacerbations is based on the vicious cycle concept, with key components of the 
disease being chronic bronchial infection, inflammation, impaired mucociliary clearance and structural lung damage. 
Treatment is primarily based on the principles of preventing or suppressing acute and chronic bronchial infection, improving 
mucociliary clearance and reducing the impact of structural lung disease (figure 1). 
Chronic airways infection, most frequently with Haemophilus influenzae and Pseudomonas aeruginosa and less 
frequently with Moraxella catarrhalis, Staphylococcus aureus and Enterobacteriaceae, stimulate and sustain lung 
inflammation. Persistent isolation of these organisms in sputum or bronchoalveolar lavage is associated with an increased 
frequency of exacerbations, worse quality of life and increased mortality [13, 14]. This is particularly the case with P. 
aeruginosa infection. A systematic review of observational studies identified that P. aeruginosa infection is associated with a 
three-fold increase in mortality risk, an almost seven-fold increase in risk of hospital admission and an average of one additional 
exacerbation per patient per year [15]. 
Inflammation in bronchiectasis is primarily neutrophilic and closely linked to persistent bacterial infection. Excessive neutrophilic 
inflammation is linked to an increased frequency of exacerbations and rapid lung function decline through degradation of 
airway elastin, among other mechanisms [16–19]. The available data also support a role for cell-mediated immunity, 
specifically T-cells in the pathophysiology of bronchiectasis, but the role of other inflammatory cells is less clear [17]. 
Mucociliary clearance is impaired by the impact of structural bronchiectasis, airway dehydration, excess mucus volume and 
viscosity. More than 70% of bronchiectasis patients expectorate sputum daily with highly variable sputum volumes. 
Treatment aims to prevent mucus stasis and the associated mucus plugging, airflow obstruction and progressive lung damage 
[20]. 
Structural changes in the lung associated with disease include bronchial dilatation, bronchial wall thickening, and mucus 
plugging as well as small airways disease and emphysema. More than 50% of patients have airflow obstruction, but restrictive, 
mixed ventilatory pattern and preserved lung function are 
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FIGURE 1 Treatments for bronchiectasis considered in this guideline according to the vicious cycle concept of bronchiectasis. 
 
 
also frequently observed. Breathlessness is due to the impact of airflow obstruction, impaired gas transfer, exercise 
deconditioning and the impact of comorbidities [21–24]. Breathlessness is one of the strongest predictors of mortality [9, 14]. 
Therapies may aim to treat airflow obstruction (e.g. bronchodilators), to improve exercise capacity ( pulmonary 
rehabilitation), or to remove poorly functioning or diseased lung (e.g. surgery). 
Bronchiectasis has long been a neglected disease. The prevalence of bronchiectasis has been estimated at 53 to 566 cases per 100 
000 inhabitants. Prevalence increases with age and female gender [25–29]. 
QUINT et al. [28] described that age-adjusted mortality rate for bronchiectasis was 1437.7 per 100 000. Several longitudinal 
studies have described up to a 30% mortality at 1-year follow-up after suffering an exacerbation [30, 31], particularly in the 
presence of COPD [32]. 
The economic burden of this disease has been estimated to be similar to COPD; this increases with disease severity, 
hospitalisations, need for intensive care, and use of inhaled antibiotics [25, 26, 30, 33, 34]. No therapies are currently 
specifically licensed by regulatory authorities in Europe or the USA for the treatment of bronchiectasis. Historically, 
treatment has been extrapolated from the management of cystic fibrosis bronchiectasis, but randomised clinical trials and 
clinical experience has demonstrated that treatment responses are different and that specific guidance for bronchiectasis not 
due to cystic fibrosis is necessary [35, 36]. 
National guidelines are available in Europe: the Spanish guidelines (SEPAR) were published in 2008 [37] and the British Thoracic 
Society (BTS) guidelines were published in 2010 [38]. Aspects of management of acute exacerbations in bronchiectasis were 
addressed in the European Respiratory Society (ERS)/European Society for Clinical Microbiology and Infectious Diseases lower 
respiratory tract infections guidelines published in 2011 [39]. However, to date, there are no international guidelines for the 
management of adult bronchiectasis published and no national guidelines published in Europe in the past 5 years. 
 
Methods 
This guideline was developed by a European Respiratory Society bronchiectasis task force chaired by 
E. Polverino (Spain) and J.D. Chalmers (UK). The task force included specialists in respiratory medicine with recognised expertise 
in the management of patients with lung infections, as well as a microbiologist, an immunologist, a physiotherapist, a general 
practitioner, a thoracic surgeon, three patient representatives from the European Multicentre Bronchiectasis Audit and 
Research Collaboration (EMBARC)/European Lung Foundation (ELF) bronchiectasis patient advisory group and two ERS 
methodologists. 
The guideline panel held four face-to-face meetings, beginning in January 2015. The most relevant clinical questions on the 
management of bronchiectasis in adults (for both clinicians and patients) were debated. A total of nine clinical questions 
were formulated using the PICO format (Patients, Intervention, Comparison, Outcomes) and systematic reviews were 
conducted to answer these specific questions, until September 2016 when the final guideline recommendations were 
discussed and agreed. Regular teleconferences and discussions via e-mail around individual topics were held. The patient 
representatives were actively involved in all discussions as full members of the guideline committee, provided input into the 
final recommendations and will be involved in developing a lay version of the guideline. 
 
Impaired mucociliary clearance 
Long-term mucoactive treatments 
Airway clearance 
Inflammation 
Long-term anti-inflammatory 
therapies 
Structural lung disease 
Long-term bronchodilator therapy 
Surgery 
Pulmonary rehabilitation 
Chronic bronchial infection 
Long-term inhaled or oral antibiotic therapy 
Eradication of new pathogenic microorganisms 
Antibiotic treatment of exacerbations 
ERS GUIDELINES  |  E. POLVERINO ET AL. 
 5 
 
 
 
 
Disclosure of potential conflicts of interest 
Committee members disclosed all potential conflicts of interest according to ERS policy. Conflicted members were asked 
to abstain from discussions and voting on recommendations in which they were considered to have potential conflicts. 
Compliance with the conflict of interest policy was monitored by the chairs. The methodologists were non-voting members of 
the panel. 
 
Systematic review 
An experienced external librarian designed and ran a search strategy using MeSH terms and keywords for each clinical question, 
in collaboration with the methodologists. More details of the search strategy are shown in the supplementary material. The 
search retrieved 3038 records; after removal of duplicates and exclusion of citations that did not meet the established 
inclusion criteria, a total of 48 references were included in the evidence summaries (figure 2; supplementary material). 
 
Assessment of the level of evidence and degree of recommendations 
The panel selected outcomes of interest for each clinical question a priori, based on their relative importance to adult 
patients with bronchiectasis and to clinical decision making (supplementary material). 
We followed the GRADE approach to assess the confidence in the evidence (quality) and the degree of recommendations 
[2]. Recommendations are graded as strong or conditional after considering the quality of the evidence, the balance of desirable 
and undesirable consequences of compared management options, the assumptions about the relative importance of 
outcomes, the implications for resource use, and the acceptability and feasibility of implementation [40]. 
Evidence summary of findings tables and evidence to decisions frameworks were generated for each clinical question 
(supplementary material) [41]. Based on these formats, the panel formulated the clinical recommendations and decided on 
their strength by consensus, or, if required, by voting. Following the GRADE approach, strong recommendations are 
worded as “we recommend”, while conditional recommendations are worded as “we suggest”. 
 
Question 1: Is standardised testing for the cause of bronchiectasis beneficial when 
compared with no standardised testing? 
Recommendations 
We suggest the minimum bundle of aetiological tests in adults with a new diagnosis of bronchiectasis (conditional 
recommendation, very low quality of evidence) is: 1) differential blood count; 2) serum immunoglobulins 
(total IgG, IgA and IgM); and 3) testing for allergic bronchopulmonary aspergillosis (ABPA). 
It is expected that sputum culture is undertaken for monitoring purposes of bacterial infection. Mycobacterial culture 
may be helpful in selected cases where NTM are suspected as an aetiological cause of bronchiectasis. Additional tests may be 
appropriate in response to specific clinical features, or in patients with severe or rapidly progressive disease. 
 
Summary of the evidence 
The SEPAR and BTS guidelines have previously recommended a routine “bundle” of tests at diagnosis to identify possible 
underlying causes of bronchiectasis [37, 38]. Our systematic review identified no publications which directly addressed 
whether routine aetiological investigation protocols provide benefit compared to clinically driven investigations or no testing. 
Four observational studies were identified which describe the percentage of adult patients (7−37%) whose management 
changed following investigation of aetiology while no other relevant outcomes were reported [42–45]. 
 
Justification of the recommendation 
Measurement of circulating white cell count and differential is suggested in all patients. The presence of lymphopenia or 
neutropenia may suggest primary or secondary immune deficiency, while lymphocytosis may suggest secondary immune 
deficiency as a consequence of haematological malignancy. 
Serum IgA, IgM, IgG are generally tested together, and we have considered them jointly. Low IgG, with or without low IgM or low 
IgA may indicate a defective antibody production that is an important modifiable cause of bronchiectasis, and 2–8% of 
patients with bronchiectasis have common variable immune deficiency [42–44]. Importantly, in these cases 
immunoglobulin replacement treatment can result in significant improvement in short and long-term outcomes. The cost of 
serum immunoglobulin testing is low and testing is readily available. 
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Records excluded by title/abstract 
n=97 systematic reviews 
n=1894 clinical trials 
n=849 observational studies 
Full-text articles excluded 
n=21 systematic reviews 
n=80 clinical trials 
n=49 observational studies 
Identification of relevant references after 
July 2015 
n=2 systematic reviews (PICO 8 and 9) 
n=1 clinical trial 
Studies included up to 2015 
n=22 systematic reviews 
n=24 clinical trials 
n=5 observational studies (PICO 1) 
Records screened after duplicates removed 
n=138 systematic reviews 
n=1997 clinical trials 
n=903 observational studies 
Full-text articles assessed for eligibility 
n=41 systematic reviews 
 
 
 
 
 
n=103 clinical trials 
 
 
 
 
 
n=54 observational studies (PICO 1) 
 
Studies included up to July 2015 
n=20 systematic reviews 
 
 
 
 
 
n=23 clinical trials 
 
 
 
 
 
n=5 observational studies (PICO 1) 
 
 
 
 
 
 
 
 
 
 
 
 
PICO 1: 5 PICO 2: 1 PICO 3: 0 
PICO 4: 7 PICO 5: 10 PICO 6: 3 
PICO 7: 6 PICO 8: 1 PICO 9: 8 
 
 
PICO 1: 0 PICO 2: 12 PICO 3: 8 
PICO 4: 3 PICO 5: 26 PICO 6: 10 
PICO 7: 2 PICO 8: 7 PICO 9: 35 
 
 
 
 
 
 
 
 
PICO 1: 0 PICO 2: 0 PICO 3: 0 
PICO 4: 6 PICO 5: 8 PICO 6: 3 
PICO 7: 1 PICO 8: 0 PICO 9: 2 
 
 
PICO 1: 0 PICO 2: 3 PICO 3: 0 
PICO 4: 2 PICO 5: 2 PICO 6: 2 
PICO 7: 0 PICO 8: 0 PICO 9: 14 
 
 
 
 
 
 
 
 
 
 
FIGURE 2 PRISMA flow diagram. 
 
The geographic distribution of ABPA is thought to be variable, but establishing diagnosis alters management [45]. 
Hence the panel advises routine screening of all patients for ABPA at diagnosis. The generally recommended screening tests 
for ABPA are total serum IgE, specific IgG to Aspergillus, and specific IgE to Aspergillus or, as an alternative, skin prick tests to 
Aspergillus [46, 47]. 
A range of other tests may be appropriate in specific circumstances. In patients with radiological features of NTM or clinical 
features such as weight loss, haemoptysis, rapid deterioration or symptoms non-responsive to standard therapy, three 
sequential daily sputum cultures for mycobacterial cultures or a single bronchoalveolar lavage should be considered [48]. Some 
authorities recommend measuring antibody responses to S. pneumoniae 23 valent polysaccharide vaccine (PPV23) in order to 
identify individuals with specific polysaccharide antibody deficiency [37, 38]. Failure to make an antibody response to 
PPV23 (four-fold increase in titre at 4–6 weeks) may suggest a defect in carbohydrate antigen responses. However, due to the 
large variability in individual antibody response to PPV23 and in testing protocols, this 
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evaluation should not be performed without specialist support. Testing for cystic fibrosis with measurement of 
sweat chloride, other biomarkers of cystic fibrosis transmembrane conductance regulator (CFTR)-mediated chloride ion transport 
and CFTR gene mutation analysis should be considered in young adults or with specific clinical features of cystic fibrosis, 
such as upper lobe predominance of bronchiectasis on chest CT, the presence of nasal polyposis and/or chronic 
rhinosinusitis, recurrent pancreatitis, male primary infertility and/or malabsorption. Testing for primary ciliary dyskinesia 
with nasal nitric oxide, high-speed video analysis, transmission electron microscopy, immunofluorescence and/ or genetic testing 
should be considered for patients with several of the following features: persistent wet cough since childhood, situs 
anomalies, congenital cardiac defects, nasal polyposis and/or chronic rhinosinusitis, chronic middle ear disease with or 
without hearing loss, a history of neonatal respiratory distress or neonatal intensive care admittance in term infants. Refer to the 
ERS guidelines for the diagnosis of primary ciliary dyskinesia for more information [49]. The presence of basal emphysema or 
early onset airflow obstruction could suggest the need to exclude alpha1-antitrypsin deficiency. There are a wide range of other 
causes of bronchiectasis many of which can be identified by history, physical examination and CT scanning. We do not 
recommend routine testing of autoantibodies to screen for connective tissue disease, but evidence of connective tissue disease 
should be sought by history and physical examination. 
The suggested bundle is justified by the fact that, despite the lack of strong evidence, selected tests can considerably alter 
the clinical management of bronchiectasis by indicating specific therapeutic interventions such as immunoglobulin 
replacement, corticosteroids or antifungal treatment. These interventions imply significant potential benefits for some 
individuals, and minimal undesirable effects from testing for others. The patient advisory group reported that patients 
placed a high value on identifying the underlying cause of bronchiectasis. 
 
Implementation considerations 
The standard tests recommended in this bundle should be available in the majority of healthcare systems and should not present 
major implementation issues. 
 
Question 2: Are courses of 14–21 days of systemic antibiotic therapy compared to shorter 
courses (<14 days) beneficial for treating adult bronchiectasis patients with an acute 
exacerbation? 
Recommendation 
We suggest acute exacerbations of bronchiectasis should be treated with 14 days of antibiotics (conditional recommendation, 
very low quality of evidence). 
 
Summary of the evidence 
Bronchiectasis patients are typically given prolonged courses of antibiotics of 14 days’ duration for infective 
exacerbations. This recommendation is given in previous guidelines for bronchiectasis [37, 38]. It is based on expert consensus 
and studies that documented good clinical outcomes with such treatment regimens. However, the evidence base for this 
duration is poor. 
The published literature was assessed as to whether shorter (<14 days) courses of antibiotics would be as clinically effective or be 
associated with any harm compared to 14–21 days of therapy. There was no direct evidence of benefit favouring either 14–21 
days or shorter courses of antibiotic therapy. The only data comes from an indirect comparison of response at day 7 
versus day 14 in 53 patients, all receiving ciprofloxacin (with or without inhaled tobramycin) for 14 days. After pooling both 
study arms, bacterial load (MD: +0.23 cfu·mL-1 higher at day 14, 95% CI −1.55 to +2.01) and forced expiratory volume in 1 s 
(FEV1) (MD: +0.01 L at day 14, 95% CI −0.51 to +0.53) were similar at 7 and 14 days with wide confidence intervals 
including both benefit and harm. No data was available for clinical outcome such as subsequent quality of life and exacerbations 
(supplementary material) [50]. 
 
Data from other studies 
Some authors have shown a favourable impact of 14 days of antibiotics for treatment of a bronchiectasis exacerbation. One 
study of 32 exacerbations treated with 14 days of intravenous antibiotics demonstrated significant improvement in 24-h sputum 
volume, bacterial clearance, C-reactive protein, incremental walk test and SGRQ, but no improvement in spirometry [51]. A 
further study of 34 patients treated with intravenous antibiotics for 14 days demonstrated a reduction in sputum bacterial 
load and markers of airway inflammation after antibiotic treatment [7]. 
 
Justification of the recommendations 
In the absence of any direct data comparing longer and shorter courses of antibiotics, we suggest continuing the usual 
practice of treating acute exacerbations of bronchiectasis with 14 days of antibiotics 
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on the basis of the patient’s prior microbiology testing and the severity of the exacerbation. Patients have diverse views on the 
duration of antibiotics for exacerbations, with some preferring longer courses, and other patients wishing to use shorter courses 
if possible. 
 
Implementation considerations 
It is possible that shorter courses of antibiotics may be appropriate in some cases. The task force panel suggests that mild 
exacerbations, exacerbations in mild patients, those associated with pathogens more sensitive to antibiotics (e.g. S. 
pneumoniae), or patients with a rapid return to baseline state may benefit from shorter courses, but evidence supporting 
shorter course treatment is lacking. Otherwise, in patients with lack of recovery by 14 days of antibiotic therapy we suggest re-
evaluation of the patient’s clinical condition and a new microbiological investigation. Sending a sputum sample at the 
start of an exacerbation is helpful to guide choice of antibiotics in the event of inadequate response to initial therapy. Due to 
variations in antibiotic use and healthcare practices across Europe, we do not address choice of specific antibiotics, or the role 
of combination versus monotherapy in this guideline. 
Further research studies assessing the optimal duration of antibiotics are recommended. 
 
Question 3: Is eradication treatment beneficial for treating bronchiectasis patients with a 
new isolate of a potentially pathogenic microorganism in comparison to no eradication 
treatment? 
Recommendations 
We suggest that adults with bronchiectasis with a new isolation of P. aeruginosa should be offered eradication 
antibiotic treatment (conditional recommendation, very low quality of evidence). 
We suggest not offering eradication antibiotic treatment to adults with bronchiectasis following new isolation of 
pathogens other than P. aeruginosa (conditional recommendation, very low quality of evidence) 
 
Summary of the evidence 
Eradication treatment refers to any antibiotic treatment given with the express intention of achieving complete clearance 
of the pathogen from the airway. In bronchiectasis, eradication treatment regimens vary, but there is some evidence suggesting 
that a regimen including a nebulised antibiotic achieves greater rates of clearance and clinical benefits than intravenous 
treatment alone in achieving clearance of P. aeruginosa  [52]. 
Chronic airway infection in adult patients with bronchiectasis is frequent and usually associated with worse outcomes such 
as more exacerbations and poorer quality of life [15, 53]. Definitions of chronic airway infection in bronchiectasis are not 
established but a systematic review identified that the most frequent definition used in bronchiectasis studies is two or more 
isolates of the same organism at least 3 months apart in 1 year [15]. Unfortunately, in patients with persistent infections, there is 
little evidence about the beneficial effects of pathogen eradication beyond P. aeruginosa. 
We could not identify any randomised controlled trial directly addressing the question. Therefore we included two studies 
that investigated whether eradication treatment in adult patients with bronchiectasis improved clinical outcomes compared to 
the patient’s own baseline [54, 55]. Pooled analysis provides some evidence of the potential benefits of P. aeruginosa 
eradication in terms of negative sputum samples, frequency of subsequent exacerbations and quality of life, but the evidence is 
indirect and considered of low quality. 
In particular, the retrospective observational study of WHITE et al. [55] analysed different eradication treatment regimens: 
i.v. antibiotics (12 cases), i.v. antibiotics followed by inhaled antibiotics (13 cases), and oral ciprofloxacin alone. 25 patients 
across all groups received 3 months of inhaled colistin. Initial clearance rate from sputum was 80%, but 54% of all patients 
remained P. aeruginosa free at follow-up and the exacerbation rate fell from 3.93 to 2.09 per year after the eradication 
treatment. In addition, two thirds of patients experienced clinical improvement although lung function remained unchanged. 
ORRIOLS et al. [54] performed a 15-month single-masked, randomised controlled trial in 35 patients with early P. aeruginosa 
infection. These patients received initial therapy with i.v. ceftazidime or tobramycin followed by 3 months of 300 mg of 
nebulised tobramycin b.d. or placebo. At the end of follow-up (12 months), 54% of patients were free of P. aeruginosa in 
the tobramycin group versus 29% in the placebo group. Despite some potential methodological limitations, this study 
showed that the median time to recurrence of P. aeruginosa was longer in the treatment arm compared to placebo 
and numbers of exacerbations and hospital admissions were lower in the nebulised tobramycin group. The impact of 
eradication treatments on the development of antibiotic resistance was not extensively studied. This study had no control group 
and so is limited in terms of informing whether eradication is effective. 
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FIGURE 3 Three possible and alternative eradication treatment pathways based on what is commonly used in clinical practice. After each step it is recommended to repeat 
sputum sampling for Pseudomonas aeruginosa and to progress to the next step if the culture remains positive. 
 
There is no clear evidence to support one regimen over another, and therefore figure 3 illustrates some commonly used 
regimes. 
 
Justification of the recommendation 
The poor clinical outcomes associated with chronic P. aeruginosa infection, the data from one observational 
study and the clinical experience in cystic fibrosis suggests that P. aeruginosa eradication may positively influence important 
clinical outcomes including exacerbation frequency. 
There is no evidence to support eradication of organisms other than P. aeruginosa and in organisms that are not so clearly 
associated with poorer outcomes, the risk-benefit ratio is less in favour of eradication treatment. 
 
Implementation considerations 
Identification of new isolates of P. aeruginosa requires regular sputum surveillance which has resource implications. We 
suggest as a minimum that patients should have a sputum sample sent when clinically stable once per year. In circumstances 
where the date of acquisition of P. aeruginosa is uncertain, a clinical judgement must be made on the likely success or otherwise 
of an eradication attempt. This guideline does not address attempted eradication of chronic P. aeruginosa infection, where the 
infection has been present for many years, as this is thought unlikely to be successful. The quality of evidence is low and 
further research is also needed on potential side effects of eradication therapies and, particularly, the emergence of resistance or 
new infections. 
 
Question 4: Should long-term anti-inflammatory agents be used in adult patients with 
bronchiectasis? 
Recommendation: 
We suggest not offering treatment with inhaled corticosteroids to adults with bronchiectasis (conditional recommendation, 
low quality of evidence). 
We recommend not offering statins for the treatment of bronchiectasis (strong recommendation, low quality of 
evidence). 
We suggest that the diagnosis of bronchiectasis should not affect the use of inhaled corticosteroids in patients with 
comorbid asthma or COPD (best practice advice, indirect evidence). 
Total duration 
3 months 
Total duration 
3 months 
Total duration 
3 months 
Oral fluoroquinolone OR 
intravenous antibiotics PLUS 
inhaled antibiotics, e.g. 
ciprofloxacin 750 mg b.i.d. 
plus inhaled colistin 
 
Initial phase 
2 weeks 
 
 
Intravenous antibiotics, e.g. 
beta-lactam plus aminoglycoside 
 
 
 
 
Initial phase 
2 weeks 
 
 
Oral fluoroquinolone 
e.g. ciprofloxacin 750 mg b.i.d. 
 
 
 
 
Initial phase 
2 weeks 
 
 
Consider repeat sample to 
confirm persistent P. aeruginosa 
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We considered only studies of anti-inflammatory drugs that were at least 3 months in duration. Although macrolides may have 
anti-inflammatory activity their role in bronchiectasis is discussed within PICO question 5 of these guidelines (regarding 
antibiotics). We identified six systematic reviews [56–61] and three studies that met our inclusion criteria [62–64]. 
HERNANDO et al. [64] reported a double-blind randomised controlled trial over 6 months with 77 patients allocated to inhaled 
budesonide 400 μg b.d. or placebo with a primary outcome of lung function. TSANG et al. [62] reported a trial of inhaled 
fluticasone versus placebo over 12 months in 86 patients with co-primary end-points of 24 h sputum volume and 
annual exacerbation frequency. MANDAL et al. [63] studied atorvastatin in 30 patients over 6 months compared to a matched 
group receiving placebo with a primary outcome improvement in cough related quality of life measured by the 
Leicester cough questionnaire. Overall the three studies included only 193 patients. Two of the studies assessed the effects of 
anti-inflammatories on exacerbations with a wide confidence interval (rate ratio (RR) 0.99, 95% CI 0.76–1.30) [62, 64]. 
Hence no clear benefit on reducing exacerbations was noted. 
The effect on quality of life, using the SGRQ, was only reported in two studies (123 patients) [63, 64], with an observed 
improvement of 0.91 points (below the minimal clinically significant difference of 4 points, 95% CI −4.51 to +6.33). All three 
studies reported FEV1 and forced vital capacity (FVC) as lung function outcomes [62–64]. No significant benefit was seen with 
any of the treatments studied for lung function. 
The study design and small number of patients make these studies not optimal for safety assessment. Across the three 
studies the pooled estimate of suffering any adverse event was RR 2.75 (95% CI 1.21–6.25) as compared to control. The 
adverse effect profile of both inhaled corticosteroids and statins has been well described. 
The increase in pooled adverse events was largely driven by MANDAL et al. [63] who reported that adverse events led to 
withdrawal from the atorvastatin group (one case of headache, one of diarrhoea, and two of combined diarrhoea and 
headache). One was withdrawn due to liver function abnormalities at 3 months. 
10 (33%) patients receiving atorvastatin had an adverse event versus three (10%) allocated placebo (difference 23%, 
95% CI 3–43; p=0.02). 
For the inhaled corticosteroid trials in bronchiectasis, adverse event reporting was incomplete. Known and frequent local adverse 
events across all diseases include dysphonia and oropharyngeal candidiasis. More severe adverse events include: alteration of 
the hypothalamic-pituitary-adrenal axis function, pneumonia, increased intraocular pressure, formation of cataracts and decreased 
bone density. 
 
Justification of recommendations 
There are no large trials of anti-inflammatory therapies in bronchiectasis and the existing studies show minimal and, in most 
cases, no clinically significant benefits. The increased frequency of adverse events, particularly with statins, justifies a 
recommendation against their use. The guideline panel concludes that inhaled corticosteroids do not have a role in the 
routine management of bronchiectasis. Inhaled corticosteroids have an established role in the treatment of asthma and 
a proportion of patients with COPD. In the absence of specific data in adult patients with bronchiectasis and these two 
conditions, the guideline panel concludes that the presence of bronchiectasis alone should not lead to a decision to 
withdraw inhaled corticosteroids from patients with established asthma or COPD. 
 
Implementation considerations 
We recommend randomised controlled trials of inhaled corticosteroids in bronchiectasis who are naïve to inhaled corticosteroid 
therapy. Inhaled corticosteroid use is, however, already widespread in bronchiectasis. In those already treated with inhaled 
corticosteroids and no clear history of asthma or COPD a randomised controlled trial of inhaled corticosteroid withdrawal 
may help define true utility of this widely prescribed therapy. 
 
Question 5: Is long-term antibiotic treatment (⩾3 months) compared to no treatment 
beneficial for treating adult bronchiectasis patients? 
Recommendations 
We suggest offering long-term antibiotic treatment for adults with bronchiectasis who have three or more exacerbations per 
year (conditional recommendation, moderate quality evidence). 
All subsequent recommendations refer to patients with three or more exacerbations per year. 
We suggest long-term treatment with an inhaled antibiotic for adults with bronchiectasis and chronic 
P. aeruginosa infection (conditional recommendation, moderate quality evidence). 
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We suggest long-term treatment with macrolides (azithromycin, erythromycin) for adults with bronchiectasis and 
chronic P. aeruginosa infection in whom an inhaled antibiotic is contraindicated, not tolerated or not feasible (conditional 
recommendation, low quality evidence). 
We suggest long-term treatment with macrolides (azithromycin, erythromycin) in addition to or in place of an inhaled 
antibiotic, for adults with bronchiectasis and chronic P. aeruginosa infection who have a high exacerbation frequency 
despite taking an inhaled antibiotic (conditional recommendation, low quality evidence). 
We suggest long-term treatment with macrolides (azithromycin, erythromycin) for adults with bronchiectasis not 
infected with P. aeruginosa (conditional recommendation, moderate quality evidence). 
We suggest long-term treatment with an oral antibiotic (choice based on antibiotic susceptibility and patient tolerance) for 
adults with bronchiectasis not infected with P. aeruginosa in whom macrolides are contraindicated, not tolerated or 
ineffective (conditional recommendation, low quality evidence). 
We suggest long-term treatment with an inhaled antibiotic for adults with bronchiectasis not infected with 
P. aeruginosa in whom oral antibiotic prophylaxis is contraindicated, not tolerated or ineffective (conditional 
recommendation, low quality of evidence). 
We identified eight systematic reviews [65–72] and 17 relevant studies for this clinical question [36, 52, 73–86]. Our evidence 
summary suggests that long-term antibiotic use, pooling both inhaled and oral antibiotic data, reduces the number of 
exacerbations, time to first exacerbation, sputum purulence and breathlessness in adults with bronchiectasis; however, they are 
also associated with more adverse events and bacterial resistance. 
Three randomised controlled trials evaluating the effect of nebulised antibiotics in adults with bronchiectasis 
suggested beneficial effects on exacerbation frequency and/or time to first exacerbation [65, 76, 78, 83]. In a study involving 144 
adults with bronchiectasis and P. aeruginosa infection, colistin 1MU delivered twice daily through the I-neb was not associated 
with a statistically significant improvement in time to first exacerbation compared to placebo [83]. However, in a pre-
planned analysis in adherent individuals (defined as taking ⩾81% of doses recorded by the I-neb), the median (25th quartile) 
time to exacerbation was 168 (65) days versus 103 (37) days in the colistin and placebo groups, respectively ( p=0.038). A 
similar treatment effect was reported in a study evaluating nebulised liposomal ciprofloxacin in 42 adult patients with 
bronchiectasis and P. aeruginosa infection [78]. A 12-month single blind study of nebulised gentamicin in 65 adults with 
bronchiectasis predominantly infected with H. influenzae (n=26, 46%) or P. aeruginosa (n=24, 42%) showed significant 
benefits including fewer exacerbations compared to 0.9% saline-treated patients [76]. 
Three randomised controlled trials showed beneficial effects of macrolide antibiotics (azithromycin or erythromycin) on 
exacerbation frequency in adults with bronchiectasis: EMBRACE (141 patients on azithromycin or placebo for 6 months) 
[77], BAT (83 patients on azithromycin or placebo for 12 months) [80] and BLESS (117 patients on erythromycin or placebo 
for 12 months) [79]. The EMBRACE study showed the rate of event-based exacerbations was 0.59 per patient in the 
azithromycin group and 1.57 per patient in the placebo group in the 6-month treatment period (RR 0.38, 95% CI 0.26–0.54; 
p<0.0001); the BAT study showed the median (interquartile range) number of exacerbations in the azithromycin group was 0 
(0–1), compared with 2 (1–3) in the placebo group ( p<0.001); and the BLESS study showed erythromycin significantly 
reduced protocol defined exacerbations compared to placebo (mean 1.29, 95% CI 0.93–1.65 versus 1.97, 95% CI 1.45–2.48 per 
patient per year; p<0.003). Doses used in clinical trials or in clinical practice range from 250 mg azithromycin daily, 500 mg or 
250 mg three times per week, and erythromycin 400 mg twice daily. 
Historical randomised controlled trials evaluating penicillin and tetracycline based antibiotic regimens also suggest some benefit in 
adults with bronchiectasis, with two long-term studies reporting less days off work and reduced sputum purulence with 
oxytetracycline [84] or amoxicillin treatment [73]. 
Important adverse events were reported with long-term antibiotic treatment. Diarrhoea was more common with oral antibiotics 
than placebo in the macrolide studies, although treatment discontinuation was rare [66–70]. There was also a 28% increase in the 
proportion of macrolide-resistant commensal oropharyngeal Streptococci after 12 months treatment with erythromycin and a 
macrolide resistance rate of 88% following 12 months of azithromycin [79, 80]. In contrast, there was no antimicrobial 
resistance reported after 6– 12 months of nebulised colistin, dual release liposomal ciprofloxacin or gentamicin [76, 78, 83]. 
While these specific nebulised preparations were well tolerated, two phase III trials reported more frequent treatment-
related adverse events (1.4 and 1.8 times greater) and discontinuations (2.1 and 6.7 times greater) associated with 
nebulised aztreonam compared to placebo [36]. The most commonly reported 
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adverse events were breathlessness, cough and increased sputum production. The incidence of potential treatment-related 
adverse events such as QTc prolongation with macrolides, tinnitus/hearing loss with macrolides and inhaled 
aminoglycosides, and renal dysfunction with inhaled aminoglycosides is not known in people with bronchiectasis, but should 
be considered when weighing up the potential benefits and harms of long-term antibiotic treatment. 
 
 
Justification of recommendations 
The overall balance of desirable effects ( particularly fewer exacerbations), undesirable effects ( particularly gastrointestinal upset 
and antimicrobial resistance) and patient values favours long-term antibiotic treatment in selected patients (figure 4). For individuals 
with P. aeruginosa, the currently available evidence supports continuous use of nebulised colistin [83] or gentamicin [76]). 
Nebulised aztreonam is not recommended due to the lack of efficacy with regard to quality of life improvement over two 
treatment cycles and a high adverse event rate reported in the pivotal phase III trials [36]. Due to the relatively low 
number of participants with P. aeruginosa in the macrolide studies, the use of macrolide antibiotics is suggested as a second-
line option in patients with this organism [77, 79, 80]. However, for individuals with no evidence of 
P. aeruginosa infection, macrolide treatment is suggested as first-line treatment due to the high-quality evidence for 
exacerbation reduction and an acceptable side-effect profile [77, 79, 80]. 
Although the macrolide studies included a minimum exacerbation frequency of one [77], two [79] or three [80] exacerbations in 
the year preceding enrolment as an entry criterion, the mean exacerbation frequency in the year prior to enrolment in each of the 
three studies was ⩾3. Due to potential undesirable effects, the suggested threshold for starting long-term antibiotic treatment is 
⩾3 exacerbations per year. However, this threshold may be reduced for individuals with: a history of severe exacerbation, 
relevant comorbidities such as primary/secondary immunodeficiency, patients in whom exacerbations are having a 
significant impact on their quality of life or those with more severe bronchiectasis [9]. 
Before considering the prescription of long-term antibiotics, general aspects of bronchiectasis management need to be 
optimised, such as airway clearance and treating modifiable underlying causes. Careful characterisation of sputum 
pathogens (bacteria, mycobacteria and fungi) before and after implementation of long-term antibiotics is essential to direct 
antibiotic choices, monitor resistance patterns and identify treatment emergent organisms. Drug toxicity monitoring is also 
required, most notably with macrolides and inhaled aminoglycosides. 
 
 
Implementation considerations 
The use of inhaled antibiotics is associated with a 10–32% risk of bronchospasm [76, 87] and a supervised test dose with pre- and 
post-spirometry is recommended. Prior inhalation of a short-acting bronchodilator may prevent bronchospasm and, therefore, is 
advisable. 
 
 
 
 
 
 
FIGURE 4 Summary of recommendations for long-term antibiotic treatment. 
Combined oral and 
inhaled antibiotic 
treatment 
Long-term targeted 
oral antibiotic 
Long-term inhaled 
antibiotic treatment 
Long-term 
macrolide treatment 
P. aeruginosa infection Non-P. aeruginosa infection 
Lack of response or intolerance 
Inadequate response 
Lack of response 
or intolerance 
Optimise airway clearance 
Treat underlying causes 
≥3 exacerbations per year 
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Prior to long-term treatment with macrolides, we recommend excluding active NTM infection because macrolide 
monotherapy can increase the risk of macrolide resistance in NTM. 
No cost-effectiveness studies were identified regarding the use of long-term antibiotics in adult patients with bronchiectasis 
and further research will be required to determine if cyclical or continuous treatment ( possibly involving combinations of 
preparations) is optimal in terms of exacerbation frequency reduction, treatment burden and risk of antimicrobial resistance. 
Figure 4 summarises the approach to long-term antibiotic treatment in adults with bronchiectasis summarising the above 
guideline recommendations. 
 
Question 6: Is long-term mucoactive treatment (⩾3 months) compared to no treatment 
beneficial for treating adult bronchiectasis patients? 
Recommendation 
We suggest offering long-term mucoactive treatment (⩾3 months) in adult patients with bronchiectasis who have difficulty in 
expectorating sputum and poor quality of life and where standard airway clearance techniques have failed to control 
symptoms (weak recommendation, low quality evidence). 
We recommend not to offer recombinant human DNase to adult patients with bronchiectasis (strong recommendation,  
moderate  quality evidence) 
 
Summary of the evidence 
Airway clearance adjuncts such as mucolytics and hyperosmolar agents alter mucus viscosity and/or enhance mucociliary 
clearance. We identified three systematic reviews [88–90] and five relevant studies meeting inclusion criteria for this clinical 
question [35, 91–94]. Of these five randomised controlled trials, two were performed with dry powder mannitol at doses of 
320 mg (n=343) [93] and 400 mg twice daily (n=461) [94], one with nebulised recombinant human DNase at a dose of 2.5 mg 
twice daily (n=349) [35], and two with nebulised hypertonic saline (one with 4 mL 7% once daily [91] or 5 mL 6% twice daily [92], 
n=28 and n=40 respectively). Only in two studies [35, 93] was the treatment compared to placebo. In one study with mannitol 
[94] and in both studies with hypertonic saline [91, 92], the treatment was compared to low dose mannitol (50 mg twice daily) 
[94] and isotonic saline [91], respectively. Three previous meta-analyses of mucoactive and inhaled hyperosmolar agents in 
bronchiectasis prior to the most recent mannitol study [93] found insufficient evidence to draw firm conclusions on the 
effect of inhaled mucoactive and hyperosmolar treatment due to the significant differences in methodology, patient groups 
and findings amongst the limited data available [88–90]. 
Patients with ⩾2 exacerbations in the previous year and a baseline minimum SGRQ score of 30 who received mannitol showed a 
significantly greater improvement in total SGRQ score compared to controls (low dose mannitol), although the difference between 
arms did not reach the minimal clinically important difference for the total SGRQ score [93]. An improvement in SGRQ components 
was shown in patients without chronic P. aeruginosa infection and with no long-term antibiotic treatment who received hypertonic 
saline 7% [92]. 
None of the mucoactive agents significantly reduced the number of exacerbations, and the exacerbation rate was higher in the 
rhDNase group compared with placebo [35]. In patients with ⩾2 exacerbations in the previous year, mannitol increased the 
time to first exacerbation [94]. In one study with hypertonic saline 7% there were reductions in health care utilisation when 
comparing prospectively collected data between hypertonic saline and isotonic saline phases [92]. 
In four studies, a tolerance test was performed at first administration: patients with mannitol-induced bronchospasm (16%) 
[93, 94] or a decrease in FEV1 of more than 10% [92] or 15% [91] after inhalation of hypertonic saline (7% and 6%, respectively) 
were excluded. 
In the 3-month study, 1.8% of patients randomised to mannitol experienced bronchospasm and 1.3% reported dyspnoea as 
opposed to none in the placebo group [93]. In the 13-month study, 20.2% of patients in the mannitol arm and 16.7% in the 
control group experienced adverse events related to study medication, most of which were judged to be mild or moderate [94]. 
Hypertonic saline was well tolerated with the number of patients with adverse events similar to those of the control groups. 
The mannitol studies both showed a significantly increased 24 h sputum weight after treatment compared to the control arms, 
consistent with improved mucociliary clearance [93, 94]. Mean 24 h sputum weight decreased progressively during the study in 
both mannitol and control arms of both studies, but remained higher in the mannitol arms throughout. 
No change in lung function was observed in the studies with mannitol [93, 94] or hypertonic saline 6% [91]. However, a 
significant improvement in FEV1 and FVC was shown with hypertonic saline 7% at 3 months [92]. In contrast, a decrease in 
FEV1 was demonstrated in patients treated with RhDNase. 
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Short- or long-acting bronchodilators 
 
Mucolytic/physiotherapy adjuncts 
 
Airway clearance 
 
 
There is insufficient evidence to permit evaluation of the use of oral mucolytics such as carbocisteine for bronchiectasis [89]. 
 
Justification of the recommendation 
In summary, despite the wide heterogeneity in studies (agent used, study design and treatment duration), overall the literature 
showed a small improvement in the time to first exacerbation with a slightly elevated but acceptable adverse event profile 
with inhaled long-term mucoactive agents. The reported improvements in quality of life indicate that a proportion of 
patients will experience a significant benefit with these agents, but many patients will not. 
The current research evidence and the ELF/EMBARC bronchiectasis patient advisory group suggest that patients give 
intermediate value to this treatment and acknowledge difficulties with its administration. Mucoactive therapy is time-
consuming and the therapeutic equipment, in the case of nebulisers, may be difficult to take outside of the patient’s home. 
 
Implementation considerations 
The indication and type of treatment given should be tailored to each individual patient according to their baseline symptom 
profile (frequency and severity of exacerbations, quality of life, bronchial hyperreactivity, and sputum viscosity), baseline lung 
function and patient preferences. We suggest testing tolerance prior to starting therapy and to consider beta-agonist 
premedication. 
Larger studies should be considered in the future to investigate optimal treatment, dosages, durations and combinations. 
 
Question 7: Is long-term bronchodilator treatment (⩾3 months) compared to no treatment 
beneficial for adult bronchiectasis patients? 
Recommendations 
We suggest not routinely offering long-acting bronchodilators for adult patients with bronchiectasis (conditional 
recommendation, very low quality of evidence) 
We suggest to offer long acting bronchodilators for patients with significant breathlessness on an individual basis 
(weak recommendation, very low quality of evidence). 
We suggest using bronchodilators before physiotherapy, inhaled mucoactive drugs, as well as before inhaled antibiotics, in 
order to increase tolerability and optimise pulmonary deposition in diseased areas of the lungs (good practice point, indirect 
evidence). 
We suggest that the diagnosis of bronchiectasis should not affect the use of long acting bronchodilators in patients with 
comorbid asthma or COPD (good practice point, indirect evidence) [95, 96]. 
Where multiple inhaled therapies are used in the same patient, the sequence of treatments shown in figure 5 is commonly 
used by members of the task force. 
 
Summary of the evidence 
Very limited and indirect evidence is available for the benefit of the long-term treatment with bronchodilators 
from a systematic review that included a single trial, comparing high-dose inhaled 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 5 Flowchart of multiple 
sequential airways treatment 
administration in adult patients with 
bronchiectasis. 
 
Inhaled antibiotics 
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corticosteroids to medium-dose inhaled corticosteroid/long acting beta-agonist combination [97]. The results from this 
study indicate some positive effects on symptom control/symptomatic improvement, in particular decreased dyspnoea, 
better cough control, better health-related quality of life (measured by SGRQ symptoms domain), and reduced use of β2-
agonist rescue medication. Specific side-effects were generally mild (tremor, nervousness and tachycardia). A systematic review 
identified major methodological and reporting concerns relating to this trial [56]. However, extrapolating evidence from 
populations with other obstructive airway diseases some bronchiectasis subpopulations may benefit from bronchodilators, in 
particular subjects with chronic obstructive airflow limitation (FEV1/FVC <0.7; with or without FEV1 reversibility to 
bronchodilators), or associated asthma in combination with inhaled corticosteroids [95, 96]. 
 
Justification of the recommendations 
We suggest the use of bronchodilators in patient with significant breathlessness due to the feasibility of application, the easy 
availability at a primary care level, the comparatively low treatment costs, and a putatively positive ratio of benefits to 
adverse events. Appropriate inhalation device selection and inhaler technique training are recommended. If treatment with 
bronchodilators does not result in a reduction in symptoms it should be discontinued. There is no evidence to support the use of 
bronchodilators routinely as part of the management of bronchiectasis patients without symptomatic breathlessness. According 
to both research evidence and patient advisory group feedback, it seems that patients regard this as a low risk and low burden 
intervention. 
 
Implementation considerations 
The intervention is easy to administer and acceptable to the majority of patients. Further investigator-driven research 
on the benefit of bronchodilators in bronchiectasis in various clinical situations is needed. 
 
Question 8: Are surgical interventions more beneficial compared to standard (non-
surgical) treatment for adult bronchiectasis patients? 
Recommendation 
We suggest not offering surgical treatments for adult patients with bronchiectasis with the exception of patients with localised 
disease and a high exacerbation frequency despite optimisation of all other aspects of their bronchiectasis management 
(weak recommendation, very low quality of evidence). 
 
Summary of the evidence 
The rationale for surgical treatment of bronchiectasis is to break the vicious circle of bronchiectasis by removing the lung 
segments that are no longer functional, and preventing the contamination of adjacent lung zones. The most frequent indication 
for the operation is recurrent infections with chronic symptoms such as productive cough, purulent sputum and haemoptysis [98, 
99]. 
Lobectomy is the most frequently performed operation, but numerous options have been described (e.g. segmentectomy 
and pneumonectomy) [100–102]. Surgery is the procedure of choice for massive haemoptysis refractory to bronchial 
artery embolisation, but emergency surgery in unstable patients is associated with higher morbidity and mortality reaching 
37% [103]. Although bilateral bronchiectasis (reported in 5.8 to 30% of surgical series) are not an absolute contraindication 
for surgery [104], other options such as prolonged conservative treatment or bronchial artery embolisation are frequently used 
as an alternative. The video-assisted thoracoscopic surgery (VATS) is often preferred to better preserve lung function or 
reduce scarring. In comparison with open surgery, VATS has been reported to produce comparable symptomatic 
improvement (94 versus 88%), but with shorter hospital stay, fewer complications (17.5 versus 23.7%) and less pain 
after VATS procedures [105]. Contraindications to VATS include major parenchymal or pleural fibrosis, and calcified nodes close to 
the hilar vessels. 
No randomised controlled trials of surgical treatment versus standard care were identified. A meta-analysis included 38 
observational studies with 5541 patients, dealing with efficacy and safety of different surgical interventions for adult patients with 
bronchiectasis focused on three main outcomes: mortality, morbidity (adverse events) and quality of life improvement 
(symptomatic changes defined as reduction or alleviation of preoperative symptoms) [98]. 
The pooled mortality from 29 studies that focused on adult patients was 1.4% (95% CI 0.8%–2.5%) [98]. Post-operative pooled 
morbidity for adults was analysed in 26 observational studies and was 16.2% (95% CI,12.5%–19.8%) [98]. It needs to be 
emphasised that there are no data comparing morbidity to continued medical non-surgical management alone. Moreover, 
according to the aforementioned studies, some of the morbidity is considered relatively minor (air leak, atelectasis, wound 
infection). Symptomatic changes were analysed in 26 observational studies. In the pooled meta-analysis, complete alleviation of 
symptoms was 
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seen in 71.5% (95% CI 68–74.9) and reduction of preoperative symptoms was seen in 20.2% of the adult population (95% CI 
17.3–23.1) [98]. Other research has shown that extent of residual bronchiectasis and 
P. aeruginosa infection were reported as unfavourable prognostic factors [99]. 
 
Justification of the recommendations 
Overall, surgical interventions seem to be beneficial only in very carefully selected patients requiring the best risk-benefit 
profile of improved symptoms against the morbidity associated with surgery. Feedback from the ELF/EMBARC patient advisory 
group suggests that patients would choose surgery only if there was no effective medical option for treatment and this feedback 
informs the recommendation. 
 
Implementation considerations 
Involvement of an experienced surgeon in partnership with an expert respiratory physician is advisable if surgical treatment is 
being considered. Attention should be paid to pre-operative nutritional status and pulmonary rehabilitation. More research is 
needed on surgical interventions. Although a randomised trial would be very challenging future studies should include a 
matched control population with meticulous description of other treatments used in both populations. 
 
Question 9: Is regular physiotherapy (airway clearance and/or pulmonary rehabilitation) more 
beneficial than control (no physiotherapy treatment) in adult bronchiectasis patients? 
Recommendations 
We suggest that patients with chronic productive cough or difficulty to expectorate sputum should be taught an airway 
clearance technique (ACT) by a trained respiratory physiotherapist to perform once or twice daily (weak recommendation, 
low quality of evidence). 
We recommend that adult patients with bronchiectasis and impaired exercise capacity should participate in a pulmonary 
rehabilitation programme and take regular exercise. All interventions should be tailored to the patient’s symptoms, physical 
capability and disease characteristics (strong recommendation, high quality of evidence). 
 
Summary of the evidence (figure 6) 
In bronchiectasis, it is a common belief that physiotherapy can improve mucus clearance and reduce lung inflammation and risk 
of infection. In addition, it is well accepted by patients. Respiratory physiotherapy includes ACTs and pulmonary rehabilitation 
[106, 107]. ACTs consist of breathing techniques, e.g. active cycle of breathing and autogenic drainage, sometimes 
combined with an instrument, e.g. flutter or 
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FIGURE 6 Chest physiotherapy interventions flow chart based on clinical experience from the task force panel. AD: autogenic drainage; ELTGOL: total slow expiration with 
open glottis and infralateral position; ACBT: active cycle of breathing techniques; PEP: positive expiratory pressure; T-PEP: temporary positive expiratory pressure; 
HFCWO: high frequency chest wall oscillation. 
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  TABLE 2 Summary of PICO questions and recommendations   
 
Question Title Recommendations 
 
 
Question 1 Is standardised testing for the cause of bronchiectasis beneficial when 
compared with no standardised testing? 
 
 
 
 
 
 
 
 
 
 
 
Question 2 Are courses of 14–21 days of systemic antibiotic therapy compared to 
shorter courses (<14 days) beneficial for treating adult 
bronchiectasis patients with an acute exacerbation? 
 
 
 
Question 3 Is an eradication treatment beneficial for treating bronchiectasis patients 
with a new isolate of a potentially pathogenic microorganism in 
comparison to no eradication treatment? 
 
 
 
Question 4 Is long-term (⩾3 months) anti-inflammatory treatment compared to no 
treatment beneficial for treating adult bronchiectasis patients? 
 
 
 
 
 
 
Question 5 Is long-term antibiotic treatment (⩾3 months) compared to no 
treatment beneficial for treating adult bronchiectasis patients? 
We suggest the minimum bundle of aetiological tests in adults with a new 
diagnosis of bronchiectasis (conditional recommendation, very low 
quality of evidence) is: 
1) Differential blood count 
2) Serum immunoglobulins (total IgG, IgA, IgM) 
3) Testing for allergic bronchopulmonary aspergillosis 
It is expected that sputum culture is undertaken for monitoring purposes of 
bacterial infection. Mycobacterial culture may be helpful in selected cases 
where non-tuberculous mycobacteria are suspected as an aetiological cause 
of bronchiectasis. 
Additional tests may be appropriate in response to specific clinical features, 
or in patients with severe or rapidly progressive disease. 
We suggest acute exacerbations of bronchiectasis should be treated with 14 
days of antibiotics (conditional recommendation, very low quality of 
evidence). 
It is possible that shorter or longer courses of antibiotics may be appropriate 
in some cases, depending on specific clinical conditions (such as exacerbation 
severity, patient response to treatment, or microbiology). 
We suggest that adults with bronchiectasis with a new isolation of 
P. aeruginosa should be offered eradication antibiotic treatment 
(conditional recommendation, very low quality of evidence). 
We suggest not offering eradication antibiotic treatment to adults with 
bronchiectasis following new isolation of pathogens other than P. 
aeruginosa (conditional recommendation, very low quality of 
evidence). 
We suggest not offering treatment with inhaled corticosteroids to adults with 
bronchiectasis (conditional recommendation, low quality of evidence). 
We recommend not offering statins for the treatment of bronchiectasis 
(strong recommendation, low quality of evidence). 
We suggest that the diagnosis of bronchiectasis should not affect the use of 
inhaled corticosteroids in patients with comorbid asthma or chronic 
obstructive pulmonary disease (best practice advice, indirect evidence). 
We suggest offering long-term antibiotic treatment for adults with 
bronchiectasis who have three or more exacerbations per year (conditional 
recommendation, moderate quality of evidence). 
All subsequent recommendations refer to patients with three or more 
exacerbations per year. 
We suggest long-term treatment with an inhaled antibiotic for adults with 
bronchiectasis and chronic P. aeruginosa infection (conditional 
recommendation, moderate quality of evidence). 
We suggest macrolides (azithromycin, erythromycin) for adults with 
bronchiectasis and chronic P. aeruginosa infection in whom an inhaled 
antibiotic is contraindicated, not tolerated or not feasible (conditional 
recommendation, low quality of evidence). 
We suggest macrolides (azithromycin, erythromycin) in addition to or in place 
of an inhaled antibiotic, for adults with bronchiectasis and chronic P. 
aeruginosa infection who have a high exacerbation frequency despite taking 
an inhaled antibiotic (conditional recommendation, low quality of 
evidence). 
We suggest long-term macrolides (azithromycin, erythromycin) for adults 
with bronchiectasis not infected with P. aeruginosa (conditional 
recommendation, moderate quality of evidence). 
We suggest long-term treatment with an oral antibiotic (choice based on 
antibiotic susceptibility and patient tolerance) for adults with bronchiectasis 
not infected with P. aeruginosa in whom macrolides are contraindicated, 
not tolerated or ineffective (conditional recommendation, low quality of 
evidence). 
Continued 
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  TABLE 2 Continued   
 
Question Title Recommendations 
 
 
 
 
 
 
 
 
 
 
Question 6  Is long-term mucoactive treatment (⩾3 months) compared to no treatment 
beneficial for treating adult bronchiectasis patients? 
 
 
 
 
 
Question 7 Is long-term bronchodilator treatment (⩾3 months) compared to no 
treatment beneficial for adult bronchiectasis patients? 
 
 
 
 
 
 
 
 
 
 
 
 
Question 8  Are surgical interventions more beneficial compared to standard (non-
surgical) treatment for adult bronchiectasis patients? 
 
 
Question 9  Is regular physiotherapy (airway clearance and/or pulmonary rehabilitation) 
more beneficial than control (no physiotherapy) in adult bronchiectasis 
patients? 
We suggest long-term treatment with an inhaled antibiotic for adults with 
bronchiectasis not infected with P. aeruginosa in whom oral antibiotic 
prophylaxis is contraindicated, not tolerated or ineffective (conditional 
recommendation, low quality of evidence). 
Long-term antibiotic therapy should be considered only after optimisation 
of general aspects of bronchiectasis management (airway clearance and 
treating modifiable underlying causes). 
We suggest offering long-term mucoactive treatment (⩾3 months) in adult 
patients with bronchiectasis who have difficulty in expectorating sputum and 
poor quality of life and where standard airway clearance techniques have failed 
to control symptoms (weak recommendation, low quality of evidence). 
We recommend not offering recombinant human DNase to adult patients 
with bronchiectasis (strong recommendation, moderate quality of 
evidence). 
We suggest not routinely offering long-acting bronchodilators for adult 
patients with bronchiectasis (conditional recommendation, very low 
quality of evidence). 
We suggest offering long acting bronchodilators for patients with significant 
breathlessness on an individual basis (weak recommendation, very low 
quality of evidence). 
We suggest using bronchodilators before physiotherapy, including inhaled 
mucoactive drugs, as well as before inhaled antibiotics, in order to increase 
tolerability and optimise pulmonary deposition in diseased areas of the 
lungs (good practice point, indirect evidence). 
We suggest that the diagnosis of bronchiectasis should not affect the use of 
long acting bronchodilators in patients with comorbid asthma or chronic 
obstructive pulmonary disease (good practice point, indirect evidence) 
[95, 96]. 
We suggest not offering surgical treatments for adult patients with 
bronchiectasis with the exception of patients with localised disease and a 
high exacerbation frequency despite optimisation of all other aspects of their 
bronchiectasis management (weak recommendation, very low quality of 
evidence). 
We suggest that patients with chronic productive cough or difficulty to 
expectorate sputum should be taught an airway clearance technique by a 
trained respiratory physiotherapist to perform once or twice daily (weak 
recommendation, low quality of evidence). 
We recommend that adult patients with bronchiectasis and impaired exercise 
capacity should participate in a pulmonary rehabilitation programme and 
take regular exercise. All interventions should be tailored to the patient’s 
symptoms, physical capability and disease characteristics (strong 
recommendation, high quality of evidence). 
 
 
 
 
Acapella, that modify expiratory flow and volumes or produce chest wall oscillations in order to increase mucus clearance [108–
112]. The principal effect obtained by ACTs is an increase in sputum volume [108, 112, 113] and a reduced impact of cough on 
quality of life [109, 114]. Interesting, but still preliminary data, shows reduced peripheral airways obstruction, less 
inflammatory cells in sputum and improved exercise capacity after ACTs [109, 112, 114]. The aim of a pulmonary 
rehabilitation programme is to improve exercise tolerance and quality of life through a tailored standardised exercise protocol 
[115–117]. 
We identified three systematic reviews [106, 118, 119] and several additional trials. We included a total of 14 clinical trials in our 
analysis [91, 108, 110–112, 114–117, 120–124]. 
The pooled analysis shows that pulmonary rehabilitation has a clear impact on exercise capacity immediately after the 
programme and a nonsignificant trend to improved quality of life (SGRQ) [116, 117, 
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119, 122, 123]. However, the unpooled study of MANDAL et al. [122] ( pulmonary rehabilitation duration (8 weeks) shorter 
than for pooled studies) described that improvements on exercise capacity and patient’s quality of life may be maintained for a 
longer period of time. Finally, there is one publication showing an impact of pulmonary rehabilitation (8 weeks of 
supervised exercise training and review of ACTs) decreasing the frequency of exacerbations (median 1 (interquartile 
range 1–3) versus 2 (1–3); p=0.012) over 12-month follow-up and longer time to first exacerbation (8 versus 6 months; 
p=0.047) [116]. The reported impact of both ACTs and pulmonary rehabilitation on pulmonary function is not clinically 
important [107–109, 112, 121]. 
 
Justification of the recommendations 
The evidence for airways clearance techniques is weak because the studies are small and poorly comparable due to 
methodological issues. However, most studies demonstrated a significant increase of sputum volume. The evidence is stronger 
for pulmonary rehabilitation, showing improvements in exercise capacity, cough symptoms and quality of life, and possibly a 
reduction in exacerbations. The benefits of pulmonary rehabilitation are achieved in 6 to 8 weeks and maintained for between 3 
to 6 months. Finally, there are no relevant adverse effects and the bronchiectasis patients advisory group value the intervention. 
 
Implementation considerations 
The research priorities in physiotherapy are: larger controlled studies with clinical outcomes (exacerbations, 
cough and quality of life); larger controlled studies including physiotherapy training plus mucoactive agents such as hypertonic 
saline; the role of pulmonary rehabilitation on exacerbations; and finally, the compliance with these interventions over a longer 
period of time (>12 months) [125]. 
 
Summary 
The recommendations are summarised in table 2. Management of bronchiectasis aims to reduce exacerbations, 
reduce symptoms, improve quality of life [126, 127] and reduce the risk of future complications such as lung function 
decline [128] and severe exacerbations [129]. Treatment decisions must balance the potential beneficial effects of the 
intervention against the burden of treatment and the risk of adverse events. It is important to take into account the patients 
values and preferences in all treatment decisions, alongside the history of exacerbations, quality of life [126, 127], severity of 
disease [9] and underlying aetiology [22], all of which can impact on the patients long-term outcome [130–132]. 
The purpose of clinical guidelines is to improve the quality of patient care and to promote safe, effective and cost-effective 
treatment. The majority of recommendations in this guideline are conditional and based on low quality evidence. One outcome 
of this guideline should be to promote further research into the optimal treatment of patients with bronchiectasis. 
Bronchiectasis is a rapidly evolving field and our recommendations will require revision as additional data becomes available in 
the coming years. 
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